Given the lack of effective therapy for the dry form of AMD and the reported local FHR-3 production in the damaged eye, FHR-3 inhibition by a humanized version of RETC-2 may be an effective therapeutic strategy (Figure 8). The gene discussed is CFHR3; the disease is age-related macular degeneration.